Terms: = Lung cancer AND MAF, MGC71685, 4094, ENSG00000178573 AND Clinical Outcome
3 results:
1. Variants of ERCC5 and the outcome of platinum-based regimens in non-small cell lung cancer: a prospective cohort study.
Abdalkhalek ES; Wakeel LME; Nagy AA; Sabri NA
Med Oncol; 2022 Jul; 39(10):152. PubMed ID: 35852645
[TBL] [Abstract] [Full Text] [Related]
2. Discovery and characterization of novel peptide inhibitors of the NRF2/mafG/DNA ternary complex for the treatment of cancer.
Simov V; Altman MD; Bianchi E; DelRizzo S; DiNunzio EN; Feng G; Goldenblatt P; Ingenito R; Johnson SA; Mansueto MS; Mayhood T; Mortison JD; Serebrov V; Sondey C; Sriraman V; Tucker TJ; Walji A; Wan H; Yue Y; Stoeck A; DiMauro EF
Eur J Med Chem; 2021 Nov; 224():113686. PubMed ID: 34303079
[TBL] [Abstract] [Full Text] [Related]
3. Mutational monitoring of EGFR T790M in cfDNA for clinical outcome prediction in EGFR-mutant lung adenocarcinoma.
Su KY; Tseng JS; Liao KM; Yang TY; Chen KC; Hsu KH; Yang PC; Yu SL; Chang GC
PLoS One; 2018; 13(11):e0207001. PubMed ID: 30444875
[TBL] [Abstract] [Full Text] [Related]
